Welcome to CDC stacks | Characterizing the burden of disease of particulate matter for life cycle impact assessment - 42041 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Characterizing the burden of disease of particulate matter for life cycle impact assessment
Filetype[PDF-756.73 KB]

  • Pubmed ID:
  • Pubmed Central ID:
  • Description:
    Fine particulate air pollution (PM2.5) is a major environmental contributor to human burden of disease and therefore an important component of life cycle impact assessments. An accurate PM2.5 characterization factor, i.e., the impact per kg of PM2.5 emitted, is critical to estimating "cradle-to-grave" human health impacts of products and processes. We developed and assessed new characterization factors (disability-adjusted life years (DALY)/kgPM2.5 emitted), or the products of dose-response factors (deaths/kgPM2.5 inhaled), severity factors (DALY/death) and intake fractions (kgPM2.5 inhaled/kgPM2.5 emitted). In contrast to previous health burden estimates, we calculated age-specific concentration- and dose-response factors using baseline data, from 63 U.S. metropolitan areas, consistent with the U.S. study population used to derive the relative risk. We also calculated severity factors using 2010 Global Burden of Disease data. Multiplying the revised PM2.5 dose-responses, severity factors and intake fractions yielded new PM2.5 characterization factors that are higher than previous factors for primary PM2.5 but lower for secondary PM2.5 due to NOx. Multiplying the concentration-response and severity factors by 2005 ambient PM2.5 concentrations yielded an annual U.S. burden of 2,000,000 DALY, slightly lower than previous U.S. estimates. The annual U.S. health burden estimated from PM emissions and characterization factors was 2.2 times higher.

  • Document Type:
  • Collection(s):
  • Funding:
    T32 AG027708/AG/NIA NIH HHS/United States
    T42 OH008455/OH/NIOSH CDC HHS/United States
No Related Documents.
You May Also Like: